ICON plc, (NASDAQ:ICLR) (ISIN:IE0005711209), a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries, today announced that it has acquired Timaq Medical Imaging, a leading European provider of advanced imaging services to pharmaceutical and biotech firms.
“The acquisition of Timaq will complement our existing US operations by giving ICON a European base for our Medical Imaging operations”
Headquartered in Zurich, Switzerland, Timaq was co-founded in 2003 by Gustav von Schulthess MD, PhD, MD hon, Chairman of Radiology and Director of the Nuclear Medicine Department at the University Hospital of Zurich. Professor von Schulthess is one of the pioneers of combined PET/CT imaging and was lead director of the first clinical PET/CT in the world in March 2001.
The acquisition of Timaq strengthens ICON's existing medical imaging capabilities. ICON is a leader in the use of the core imaging laboratories and has conducted over 500 imaging trials on behalf of clients across the world.
"The acquisition of Timaq will complement our existing US operations by giving ICON a European base for our Medical Imaging operations," commented Ted Gastineau President, ICON Medical Imaging. "Alongside the immediate access to an experienced imaging team, Timaq's strong links to leading medical institutions gives us access to important scientific expertise in the imaging field that will bring significant benefits to our clients."
"We are excited to be joining ICON," commented Gustav von Schulthess. "Together we can enhance and expand the range of imaging services we offer our clients, while ICON's global footprint will enable us to support even the largest multi-country imaging studies. We look forward to working closely with ICON's imaging team to continue providing innovative imaging solutions that can help expedite clients' drug development projects."
GPT-4 matches radiologist accuracy in spotting errors, cuts time and costs dramatically